Patents by Inventor Raymond F. Brown

Raymond F. Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carboline derivatives
    Patent number: 7122554
    Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: October 17, 2006
    Assignee: Lilly Icos LLC.
    Inventors: Jason S. Sawyer, Mark W. Orme, Raymond F. Brown, Alain C. Daugan, Agnes Bombrun
  • Carboline derivatives as PDE5 inhibitors
    Patent number: 6984641
    Abstract: Selective inhibitors of cGMP-specific PDE, and use of the compounds and salts and solvates thereof as therapeutic agents, are disclosed.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: January 10, 2006
    Assignee: Lilly Icos LLC.
    Inventors: Mark W. Orme, Jason S. Sawyer, Alain C. Daugan, Agnes Bombrun, Françoise Gellibert, Lisa M. Schultze, Raymond F. Brown, Romain L. Gosmini
  • Chemical compounds
    Publication number: 20040116458
    Abstract: Compounds of the general structural formula 1
    Type: Application
    Filed: January 8, 2004
    Publication date: June 17, 2004
    Inventors: Jason S. Sawyer, Mark W Orme, Raymond F Brown, Alain C Daugan, Agnes Bombrun
  • Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof
    Patent number: 5643926
    Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: July 1, 1997
    Assignee: Eli Lilly and Company
    Inventors: Raymond F. Brown, J. Jeffry Howbert, Karen L. Lobb, David A. Neel, Jon K. Reel, Beverley Greenwood
  • Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof
    Patent number: 5300514
    Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: April 5, 1994
    Assignee: Eli Lilly and Company
    Inventors: Raymond F. Brown, J. Jeffry Howbert, Karen L. Lobb, David A. Neel, Jon K. Reel, Beverley Greenwood